Septerna, Inc. Increase Decrease In Operating Lease Liability
Septerna, Inc. (SEPN) reported Increase Decrease In Operating Lease Liability of -$1.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10
- Septerna, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$545.00K.
- Septerna, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$535.00K.
- Septerna, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$485.00K, a 294.00% decline year-over-year.
- Septerna, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$461.00K, a 194.08% decline year-over-year.
- Septerna, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.85M, a 513.17% decline from fiscal 2024.
- Septerna, Inc. increase decrease in operating lease liability for fiscal 2024 was $448.00K.
- Septerna, Inc. increase decrease in operating lease liability for fiscal 2023 was -$770.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$545.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.08M 10-Q · filed 2026-08-10 | -$1.56M derived: sum of 3 quarters · filed 2026-08-10 | -$2.03M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$535.00K 10-Q · filed 2026-05-11 | -$1.02M derived: sum of 2 quarters · filed 2026-05-11 | -$1.48M derived: sum of 3 quarters · filed 2026-05-11 | -$1.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$485.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$946.00K derived: sum of 2 quarters · filed 2026-03-09 | -$1.40M derived: sum of 3 quarters · filed 2026-08-10 | -$1.85M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$461.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$916.00K derived: sum of 2 quarters · filed 2026-08-10 | -$1.37M 10-Q · filed 2025-11-10 | -$1.12M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$455.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$905.00K 10-Q · filed 2026-08-10 | -$655.00K derived: sum of 3 quarters · filed 2026-08-10 | -$165.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$450.00K 10-Q · filed 2026-05-11 | -$200.00K derived: sum of 2 quarters · filed 2026-05-11 | $290.00K derived: sum of 3 quarters · filed 2026-05-11 | $142.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $740.00K derived: sum of 2 quarters · filed 2026-03-09 | $592.00K derived: sum of 3 quarters · filed 2026-03-09 | $448.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $342.00K derived: sum of 2 quarters · filed 2025-11-10 | $198.00K 10-Q · filed 2025-11-10 | -$44.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$148.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$292.00K 10-Q · filed 2025-08-11 | -$534.00K derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$144.00K 10-Q · filed 2025-05-15 | -$386.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$770.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$528.00K 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |